MedTrace Logo

Urinary NGAL and KIM-1 After ESWL

NCT07341269 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2026-01-14

No results posted yet for this study

Summary

The goal of this prospective observational study is to evaluate the effect of different time intervals between extracorporeal shock wave lithotripsy (ESWL) sessions on renal injury using urinary biomarkers in patients with urinary system stone disease.

The main questions it aims to answer are:

Does the interval between consecutive ESWL sessions affect the degree of renal injury?

Are urinary NGAL and KIM-1 levels reliable biomarkers for detecting ESWL-related renal damage?

What is the optimal time interval between ESWL sessions to minimize renal injury?

If there is a comparison group, researchers will compare patients undergoing ESWL with different inter-session time intervals to determine whether shorter or longer intervals are associated with higher levels of renal injury biomarkers.

Participants will:

Undergo ESWL treatment for urinary system stones

Be assigned to one of two groups based on the time interval between ESWL sessions

Provide urine samples before ESWL and after three ESWL sessions

Have urinary NGAL and KIM-1 levels measured to assess renal injury

Conditions

  • Urinary Stone
  • Renal Injury

Interventions

OTHER

No Interventions

No study-specific intervention; patients receive standard-of-care SWL.

OTHER

No intervention

No study-specific intervention; patients receive standard-of-care SWL.

Sponsors & Collaborators

  • Marmara University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-06-01
Primary Completion
2025-08-01
Completion
2025-12-10

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07341269 on ClinicalTrials.gov